You are here
COVID-19 vaccine: Provisional registrations
20 June 2022
Following a thorough and independent review, the TGA has decided that the following vaccines meet the high safety, efficacy and quality standards required for use in Australia. Learn more about the COVID-19 vaccine approval process.
| Effective date | Sponsor | Name | Type |
|---|---|---|---|
|
a. 19 January 2022 b. 09 June 2022 |
Biocelect Pty Ltd on behalf of Novavax Inc |
a. For individuals aged 18 years and over b. Booster dose for individuals aged 18 years and over |
Protein vaccine |
|
a. 9 August 2021 b. 3 September 2021 c. 7 December 2021 d. 17 February 2022 |
Moderna Australia Pty Ltd |
a. For individuals aged 18 years and over b. For individuals aged 12 years and over c. Booster dose for individuals aged 18 years and over d. For individuals aged 6 years and over |
mRNA |
| 25 June 2021 | Janssen-Cilag Pty Ltd |
For individuals aged 18 years and over |
Viral vector |
|
a. 15 February 2021 b. 8 February 2022 |
AstraZeneca Pty Ltd |
VAXZEVRIA (previously COVID-19 Vaccine AstraZeneca) a. For individuals aged 18 years and over b. Booster dose for individuals aged 18 years and over |
Viral vector |
|
a. 25 January 2021 b. 22 July 2021 c. 26 October 2021 d. 3 December 2021 e. 27 January 2022 f. 7 April 2022 |
Pfizer Australia Pty Ltd |
a. For individuals aged 16 years and over b. For individuals aged 12 years and over c. Booster dose for individuals aged 18 years and over d. For individuals aged 5 years and over e. Booster dose for individuals aged 16-17 years old f. Booster dose for individuals aged 12-15 years old |
mRNA |
Consumer Medicine Information (CMI) for COVID-19 vaccines
The CMI for each vaccine is published and updated by the Australian sponsor. The CMI provides important information such as what you should know before you're given the vaccine, including if you are taking other medicines, potential side effects, and a list of both active and inactive ingredients.
- CMI for Pfizer COMIRNATY COVID-19 vaccine
- CMI for VAXZEVRIA (previously AstraZeneca COVID-19 vaccine
- CMI for COVID-19 Vaccine Janssen
- CMI for Moderna COVID-19 vaccine
- CMI for NUVAXOVID COVID-19 vaccine
Labels for for COVID-19 vaccines
To enable timely distribution of COVID-19 vaccines, international labels will be used during the initial global rollout, including in Australia.
Some information typically present on the Australian label may be absent and/or modified on the international label, as well as additional information present that is not relevant to the Australian context.
Batch release assessment of COVID-19 vaccines
The TGA ensures there is an independent quality assessment of every batch of vaccine supplied in Australia. COVID-19 vaccines will have a priority release schedule.
Learn more about the Batch release assessment of COVID-19 vaccines.
Post-approval changes
After the initial registration of a vaccine, the sponsor may request changes to the registration details, which require additional assessment and approval by the TGA.